Literature DB >> 22633152

"Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients".

B J van Wely1, F J H van den Wildenberg, P Gobardhan, T van Dalen, I H M Borel Rinkes, E B M Theunissen, J H Wijsman, M Ernst, C C van der Pol, E V E Madsen, W J Vles, C A P Wauters, J H W de Wilt, L J A Strobbe.   

Abstract

INTRODUCTION: The objective of this study was to conduct a multicentre data analysis to identify prognostic factors for developing an axillary recurrence (AR) after negative sentinel lymph node biopsy (SLNB) in a large cohort of breast cancer patients with long follow-up. PATIENTS AND METHODS: The prospective databases from different hospitals of clinically node negative breast cancer patients operated on between, 2000 and 2002 were analyzed. SLNB was performed and pathological analysis done by local pathologists according to national guidelines. Adjuvant treatment was given according to contemporary guidelines. Multivariate analysis was performed using all available variables, a p-value of <0,05 was considered to be significant.
RESULTS: A total of 929 patients who did not undergo axillary lymph node dissection were identified. After a median follow up of 77 (range 1-106) months, fifteen patients developed an isolated AR (AR rate 1,6%). Multivariate analysis showed that young age (p = 0.007) and the absence of radiotherapy (p = 0.010) significantly increased the risk of developing an AR. Distant metastasis free survival (DMFS) was significantly worse for patients with an AR compared to all other breast cancer patients (p < 0,0001).
CONCLUSION: Even after long-term follow up, the risk of developing an AR after a negative SLN in breast cancer is low. Young age and absence of radiation therapy are highly significant factors for developing an axillary recurrence. DMFS is worse for AR patients compared to patients initially diagnosed with N0 or N1 disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22633152     DOI: 10.1016/j.ejso.2012.04.016

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years.

Authors:  Yoshinari Ogawa; Katsumi Ikeda; Kana Ogisawa; Shinya Tokunaga; Hiroko Fukushima; Takeshi Inoue; Yoshihiro Mori; Akiko Tachimori; Toru Inoue; Yukio Nishiguchi
Journal:  Surg Today       Date:  2013-09-26       Impact factor: 2.549

2.  Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence.

Authors:  Ingrid G M Poodt; Guusje Vugts; Adriana J G Maaskant-Braat; Robert-Jan Schipper; Adri C Voogd; Grard A P Nieuwenhuijzen
Journal:  Ann Surg Oncol       Date:  2018-03-01       Impact factor: 5.344

3.  Predicting the extent of nodal involvement for node positive breast cancer patients: Development and validation of a novel tool.

Authors:  Ingrid van den Hoven; David van Klaveren; Nicole C Verheuvel; Raquel F D van la Parra; Adri C Voogd; Wilfred K de Roos; Koop Bosscha; Esther M Heuts; Vivianne C G Tjan-Heijnen; Rudi M H Roumen; Ewout W Steyerberg
Journal:  J Surg Oncol       Date:  2019-07-23       Impact factor: 3.454

4.  Axillary lymph node recurrence in patients with breast cancer who underwent breast reconstruction using a latissimus dorsi flap after mastectomy.

Authors:  Goshi Oda; Tsuyoshi Nakagawa; Noriko Uemura; Hiroki Mori; Mio Mori; Tomoyuki Fujioka; Iichiroh Onishi; Hiroyuki Uetake
Journal:  Mol Clin Oncol       Date:  2021-01-19

5.  Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients.

Authors:  Julia E C van Steenhoven; Anne Kuijer; Marissa C van Maaren; Marleen Roos; Sjoerd G Elias; Paul J van Diest; Sabine Siesling; Marjolein L Smidt; Liesbeth J Boersma; Thijs van Dalen
Journal:  Ann Surg Oncol       Date:  2020-03-20       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.